PMID- 25822767
OWN - NLM
STAT- MEDLINE
DCOM- 20151117
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 64
IP  - 10
DP  - 2015 Oct
TI  - A combined approach of human leukocyte antigen ligandomics and immunogenicity 
      analysis to improve peptide-based cancer immunotherapy.
PG  - 1295-303
LID - 10.1007/s00262-015-1682-8 [doi]
AB  - The breakthrough development of immune checkpoint inhibitors as clinically 
      effective novel therapies demonstrates the potential of cancer immunotherapy. The 
      identification of suitable targets for specific immunotherapy, however, remains a 
      challenging task. Most peptides previously used for vaccination in clinical 
      trials were able to elicit strong immunological responses but failed with regard 
      to clinical benefit. This might, at least partly, be caused by an inadequate 
      peptide selection, usually derived from established tumor-associated antigens 
      which are not necessarily presented as human leukocyte antigen (HLA) ligands. 
      Recently, HLA ligandome analysis revealed cancer-associated peptides, which have 
      been used in clinical trials showing encouraging impact on survival. To improve 
      peptide-based cancer immunotherapy, our group established a combined approach of 
      HLA ligandomics and immunogenicity analysis for the identification of vaccine 
      peptides. This approach is based on the identification of naturally presented HLA 
      ligands on tumor samples, the selection of tumor-associated/tumor-specific HLA 
      ligands and their subsequent testing for immunogenicity in vitro. In this review, 
      we want to present our pipeline for the identification of vaccine peptides, 
      focusing on ovarian cancer, and want to discuss differences to other approaches. 
      Furthermore, we want to give a short outlook of a potential multi-peptide 
      vaccination trial using the novel identified peptides.
FAU - Peper, Janet Kerstin
AU  - Peper JK
AD  - Department of Immunology, Institute of Cell Biology, University of Tubingen, Auf 
      der Morgenstelle 15, 72076, Tubingen, Germany, janet-peper@gmx.de.
FAU - Stevanovic, Stefan
AU  - Stevanovic S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150331
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA Antigens)
RN  - 0 (Ligands)
RN  - 0 (Peptide Fragments)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/metabolism
MH  - Clinical Trials as Topic
MH  - Female
MH  - HLA Antigens/metabolism
MH  - Humans
MH  - Immunotherapy/*methods/trends
MH  - Ligands
MH  - Molecular Targeted Therapy
MH  - Ovarian Neoplasms/immunology/*therapy
MH  - Peptide Fragments/metabolism
MH  - *Vaccines, Subunit
PMC - PMC11029747
COIS- The authors declare that they have no conflict of interest.
EDAT- 2015/03/31 06:00
MHDA- 2015/11/18 06:00
PMCR- 2015/03/31
CRDT- 2015/03/31 06:00
PHST- 2015/01/30 00:00 [received]
PHST- 2015/03/10 00:00 [accepted]
PHST- 2015/03/31 06:00 [entrez]
PHST- 2015/03/31 06:00 [pubmed]
PHST- 2015/11/18 06:00 [medline]
PHST- 2015/03/31 00:00 [pmc-release]
AID - 1682 [pii]
AID - 10.1007/s00262-015-1682-8 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2015 Oct;64(10):1295-303. doi: 
      10.1007/s00262-015-1682-8. Epub 2015 Mar 31.